Table 2.
All treated patients (N=12) |
|||
---|---|---|---|
Grade 1 | Grade 2 | Total | |
Any treatment-related adverse event | 5 (42%) | 3 (25%) | 8 (67%) |
Diarrhea | 5 (42%) | 1 (8%) | 6 (50%) |
Fatigue | 1 (8%) | 1 (8%) | 2 (17%) |
Dermatitis acneiform | 2 (17%) | - | 2 (17%) |
Mucosal inflammation | 1 (8%) | - | 1 (8%) |
Folliculitis | 1 (8%) | - | 1 (8%) |
Tinea cruris | 1 (8%) | - | 1 (8%) |
Myalgia | 1 (8%) | - | 1 (8%) |
Dysgeusia | - | 1 (8%) | 1 (8%) |
Headache | 1 (8%) | - | 1 (8%) |
Oropharyngeal pain | 1 (8%) | - | 1 (8%) |
Sinus Congestion | 1 (8%) | - | 1 (8%) |
Flushing | 1 (8%) | - | 1 (8%) |
All treatment-related toxicity was ≤ grade 2. Data are shown as n (%).